We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+11.44%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$46.1M
AUM Growth
-$4.88M
Cap. Flow
-$2.83M
Cap. Flow %
-6.15%
Top 10 Hldgs %
52.4%
Holding
53
New
2
Increased
15
Reduced
16
Closed
3

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$3.14M
2
LITS
Lite Strategy Inc
LITS
+$1.23M
3
EXEL icon
Exelixis
EXEL
+$280K
4
INCY icon
Incyte
INCY
+$71.3K
5
ALKS icon
Alkermes
ALKS
+$55.5K

Top Sells

Rank Stock Value
1
BIB icon
ProShares Ultra NASDAQ Biotechnology
BIB
+$5.11M
2
NKTR icon
Nektar Therapeutics
NKTR
+$1.15M
3
KPTI icon
Karyopharm Therapeutics
KPTI
+$671K
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$382K
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$281K

Sector Composition

Rank Sector Weight
1 Healthcare 71.92%
2 Miscellaneous 28.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKBA icon
26
Akebia Therapeutics
AKBA
$260M
$499K 1.08%
50,004
– –
RARE icon
27
Ultragenyx Pharmaceutical
RARE
$2.59B
$485K 1.05%
6,311
-980
-13% -$63.3K
AXSM icon
28
Axsome Therapeutics
AXSM
$10.8B
$427K 0.93%
133,500
– –
NKTR icon
29
Nektar Therapeutics
NKTR
$2.55B
$417K 0.9%
569
-993
-64% -$1.15M
PCRX icon
30
Pacira BioSciences
PCRX
$1.03B
$401K 0.87%
12,500
– –
ADMS
31
DELISTED
Adamas Pharmaceuticals
ADMS
$387K 0.84%
15,000
– –
CKPT
32
DELISTED
Checkpoint Therapeutics
CKPT
$336K 0.73%
11,276
– –
ICPT
33
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$335K 0.73%
3,998
-498
-11% -$36.5K
CRL icon
34
Charles River Laboratories
CRL
$14.2B
$307K 0.67%
2,734
+121
+5% +$13.1K
GILD icon
35
Gilead Sciences
GILD
$185B
$301K 0.65%
4,251
+584
+16% +$41.2K
NBIX icon
36
Neurocrine Biosciences
NBIX
$15.8B
$301K 0.65%
3,065
-167
-5% -$14.9K
UTHR icon
37
United Therapeutics
UTHR
$22.6B
$301K 0.65%
2,660
+81
+3% +$8.9K
EXEL icon
38
Exelixis
EXEL
$13.7B
$292K 0.63%
+13,555
New +$280K
TECH icon
39
Bio-Techne
TECH
$11.4B
$282K 0.61%
7,628
-408
-5% -$15.6K
IQV icon
40
IQVIA
IQV
$43.2B
$278K 0.6%
2,789
-100
-3% -$9.99K
GRFS
41
Grifois
GRFS
$5.32B
$268K 0.58%
12,442
-980
-7% -$21.4K
MDCO
42
DELISTED
Medicines Co
MDCO
$257K 0.56%
7,000
– –
BLUE
43
DELISTED
bluebird bio
BLUE
$256K 0.56%
126
+24
+24% +$54.7K
PGEN icon
44
Precigen
PGEN
$2.57B
$245K 0.53%
17,580
-898
-5% -$15.2K
ACAD icon
45
Acadia Pharmaceuticals
ACAD
$5.12B
$234K 0.51%
15,328
-21,405
-58% -$382K
PRTK
46
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$204K 0.44%
20,000
– –
CFRX
47
DELISTED
ContraFect Corporation
CFRX
$166K 0.36%
94
– –
PGNX
48
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$88K 0.19%
10,891
– –
SCTL
49
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$63K 0.14%
14,066
– –
SCYX icon
50
SCYNEXIS
SCYX
$54.9M
$55K 0.12%
416
– –
1
2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q2 2018 Portfolio in Review

As of Q2 2018, Opus Point Partners Management held 53 positions worth $46.1M, down 9.6% from $51M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Opus Point Partners Management withdrew a net $2.83M in Q2 2018, closing 3 positions and reducing 16 holdings. Its most notable exit was Karyopharm Therapeutics, an estimated $671K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 65% a quarter earlier, followed by Miscellaneous.

Against the trend, Opus Point Partners Management opened a new position in Lite Strategy Inc worth $1.58M.

  • Opus Point Partners Management's largest Q2 2018 buy was Lite Strategy Inc: 20,000 shares worth $1.58M.
  • Opus Point Partners Management added most to State Street SPDR S&P Biotech ETF in Q2 2018, an estimated $3.14M increase.
  • Opus Point Partners Management's biggest Q2 2018 reduction was ProShares Ultra NASDAQ Biotechnology, cutting an estimated $5.11M.
  • Opus Point Partners Management fully exited Karyopharm Therapeutics in Q2 2018, selling an estimated $671K.
  • Opus Point Partners Management's ten largest holdings make up 52% of its $46.1M portfolio in Q2 2018.
  • Opus Point Partners Management opened 2 new positions and closed 3 in Q2 2018.
  • Opus Point Partners Management's portfolio value fell 9.6% quarter-over-quarter to $46.1M.

Based on Opus Point Partners Management's 13F filing for Q2 2018, filed 14 Aug 2018.